Mallinckrodt (MNK -4.8%) has initiated the rolling submission of its U.S. marketing application for terlipressin for the treatment of hepatorenal syndrome type 1 (HRS-1), a type of progressive kidney failure in patients with severe liver damage.
The clinical data package was the first to be filed. It expects to complete the submission in the coming months.
Investors appear to be reacting to the timeline. In August 2019, it announced that it expected to file the application in Q1.
https://seekingalpha.com/news/3547504-mallinckrodt-launches-rolling-application-for-terlipressin-for-hrsminus-1
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.